Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

MedGenome, a leading global genomics-driven diagnostics and research services company, announced the appointment of Dr. Amit ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.

The BNY Mellon Appreciation Fund underperformed the S&P 500 Index in the second quarter of 2024. Read more here.